The results of the study indicated that Zoom RDL is technically feasible and effective for complex neuro-interventional procedures with few cases of complications
Zoom RDL is a radial access platform developed particularly for ischemic stroke treatment. (Credit: Robina Weermeijer on Unsplash)
Imperative Care has announced positive early clinical data from a single-centre evaluation of its Zoom RDL Radial Access System in patients who underwent neuro-interventional procedures.
The results, published in the Journal of Neurointerventional Surgery (JNIS), indicated that Zoom RDL is technically feasible and effective for complex neuro-interventional procedures with few cases of complications.
Zoom RDL is said to be the first radial access platform that has been particularly developed by Imperative Care for the treatment of ischemic stroke.
It offers an alternative choice to femoral access to treat stroke patients, thereby enabling the optimal outcome as per patients’ anatomies, said the California-based medical technology company.
The independent, retrospective single-centre study of Zoom RDL featured 29 patients and was conducted at the University of Chicago Medical Center. It recruited patients who went through neuro-interventional procedures from October 2022 to January this year.
During the study, Zoom RDL was used in a variety of neuro-interventional procedures, with 31% of cases being stroke thrombectomies.
The primary outcome measure of the study was effective access of the target vessel without switching to a different guide catheter or using transfemoral access.
Results demonstrated that 90% of cases and 100% of stroke patients had successful access, with most cases, at 67%, ending in TICI 2c reperfusion or better within one pass, the medical technology company said.
Furthermore, no access site or product-related issues were reported. One case of intracerebral haemorrhage and one intraprocedural thrombus formation were the two procedure-related complications.
Imperative Care stroke business general manager Ariel Sutton said: “We are pleased to see early evidence support the use of Zoom RDL in helping physicians successfully achieve radial access in patients who might not be candidates for femoral access.
“Our patient-first portfolio includes two options for intracranial access, Zoom 88 for femoral access and Zoom RDL for radial access, empowering clinicians to choose the best option for their patients based on their anatomy.
“We look forward to future results that underscore the value of the Zoom Stroke Solution in helping physicians take more control over their stroke thrombectomies for quicker, more efficient procedures.”